Drägerwerk AG & Co. KGaA
8
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
2 terminated/withdrawn out of 8 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Validation of the Measurement Accuracy of the Tcore Thermometer
Role: lead
Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography
Role: lead
Prospective, Open, Non-interventional Study to Assess the Ability of an Electrical Impedance Tomograph (PlumoVista 500)
Role: lead
Observational Study on the Application of High-Flow Therapy After Percutaneous Transfemoral Aortic Valve Replacement
Role: lead
Dräger COVID-19 Antigen Test Clinical Performance Study
Role: lead
Assessment of the Capability of PulmoVista 500 to Continuously Monitor Changes of Ventilation Over Time
Role: lead
Automated Control of Mechanical Ventilation During General Anaesthesia
Role: collaborator
Evaluation of the Concentration-prediction for Oxygen and Volatile Anesthetic Agents in the 'Draeger Perseus A500' Anesthesia Machine
Role: collaborator
All 8 trials loaded